共 50 条
- [21] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Garrido-Laguna, IgnacioDillon, Patrick M.Kabir, SujanMei, JianWade, Mark L.Yang, HuyuanStapinski, CarlFoulks, Jason M.Warner, Steven L.Whatcott, CliffordLebedinsky, ClaudiaFu, Siqing
- [22] A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2014, 20 (02) : 445 - 455Saif, Muhammad WasifTakimoto, ChrisMita, MonicaBanerji, UdaiLamanna, NicoleCastro, JanuarioO'Brien, SusanStogard, ChristopherVon Hoff, Daniel
- [23] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +Infante, Jeffrey R.Dees, E. ClaireOlszanski, Anthony J.Dhuria, Shyeilla V.Sen, SumanCameron, ScottCohen, Roger B.
- [24] A phase I dose-escalation pharmacokinetic and pharmacodynamic study of INGN 241 (Ad-mda7) in patients with advanced solid tumorsCANCER GENE THERAPY, 2003, 10 : S2 - S3Cunningham, CCRichards, DTong, AZhang, YSu, DChada, SMhashilkar, AZhou-Yang, HParker, KWilson, DNemunaitis, JMerritt, JCoffee, K
- [25] PHASE IB STUDY OF PLX3397, A CSF1R INHIBITOR, AND PACLITAXEL IN PATIENTS WITH ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2014, 25Rugo, H. S.Sharma, N.Reebel, L.Rodal, M. B.Peck, A.West, B. L.Marimuthu, A.Karlin, D. A.Dowlati, A.Le, M. H.Coussens, L. M.Wesolowski, R.
- [26] The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumorsANNALS OF ONCOLOGY, 2024, 35 : S505 - S505Wang, J.Zhuo, M.Xu, J.Zhong, J.Jia, B.Liu, R.Zhao, C.Li, J.Dong, C.Lai, L.Ma, S.Zhong, B.Zhang, T.
- [27] A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 131S - 131SWakelee, H. A.Adjei, A. A.Halsey, J.Lensing, J. L.Dugay, J. D.Hanson, L. J.Reid, J. M.Piens, J. R.Sikic, B. I.
- [28] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) studyEJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110Traynor, A.Sandler, A.Schiller, J. H.Ilagan, J.Harper, K.VerMeulen, W.Liu, G.Tye, L.Chao, R.Robert, F.
- [29] A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 463 - 471Tibes, RaoulFine, GilChoy, GavinRedkar, SanjeevTaverna, PietroOganesian, AramSahai, AmarpalAzab, MohammadTolcher, Anthony W.
- [30] Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1060 - +Daud, Adil I.Ashworth, Michelle T.Strosberg, JonathanGoldman, Jonathan W.Mendelson, DavidSpringett, GregoryVenook, Alan P.Loechner, SabineRosen, Lee S.Shanahan, FrancesParry, DavidShumway, StuartGrabowsky, Jennifer A.Freshwater, TomokoSorge, ChristopherKang, Soonmo PeterIsaacs, RandiMunster, Pamela N.